shortagewatch

Home / Companies / AbbVie

Company family · HQ US

AbbVie: medicine shortages

ABBV · NYSE

As of 2 Nov 2026, 34 AbbVie products have a reported shortage across 4 countries, covering 15 medicines.

Products short34rank #60 of 464
Medicines15active ingredients
Countries4/16
New in 90 days3-12 vs market pace
Typical duration7 monthsmedian so far
Manufacturing29%demand-driven 29%

Where

United States15Canada17Czechia1Sweden1

Which therapeutic classes

Anti-infectives12Sensory organs6Digestive tract and metabolism3Cardiovascular system2Dermatologicals2Genito-urinary system and sex hormones1Musculoskeletal system1Cancer and immune system1

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
AbbVieAbbVie: Manufacturing problem 2 (6%)6%AbbVie: Increased demand 2 (6%)6%AbbVie: Commercial decision or withdrawal 1 (3%)AbbVie: Other 2 (6%)6%AbbVie: Not stated 27 (79%)79%All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

When its current shortages began

025710Dec: 0Jan ’25: 0Feb: 0FebMar: 0Apr: 0May: 0MayJun: 0Jul: 0Aug: 1AugSep: 0Oct: 0Nov: 0NovDec: 0Jan ’26: 1Feb: 0FebMar: 6Apr: 1May: 0MayJun: 1Jul: 7Aug: 0AugSep: 3Oct: 0Nov: 0Nov

Long-run trend in Canada

Canada dashboard
02550751002017: 320172018: 1520182019: 5520192020: 2420202021: 920212022: 1720222023: 1720232024: 720242025: 620252026: 82026

Canada publishes every report since 2017, so it shows whether this company is reporting more or fewer shortages over time. The current year is partial.

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158AbbVie34

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7AbbVie: 34 / 15AbbVie

Further right: more products short. Higher: more different medicines affected.

Medicines short

MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Lopinavir and Ritonavir824 Jul 2026Not stated3/16
Ritonavir45 Jun 2026Not stated6/16
Mesalazine3not givenNot stated11/16
Acitretin2not givenNot stated2/16
Bezafibrate1not givenNot stated4/16
Bimatoprost11 Apr 2011Other3/16
Ciclosporin18 Sep 2026Increased demand6/16
Fluorometholone19 Sep 2026Increased demand2/16
Glyceryl Trinitrate114 Apr 2026Not stated6/16
Ofloxacin112 Aug 2025Manufacturing problem2/16
Prednisolone and Antiinfectives1not givenNot stated1/16
Progesterone127 Mar 2026Not stated5/16
Risankizumab131 Jan 2024Commercial decision or withdrawal1/16
Risedronic Acid11 Aug 2018Other3/16
Timolol, Combinations19 Sep 2026Manufacturing problem9/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.